AEON Biopharma AEON 深 滬
等待開盤 10-08 09:30:00 美东时间
0.3095
+0.020
+6.83%
華盛通- 最 高0.3329
- 今 開0.2855
- 成交量 284.32万股
- 最 低 0.285
- 昨 收 0.2897
- 總市值 1.54万
- 52周最高 1.45
- 市盈率 靜 --
- 換手率 5699.86%
- 52周最低 0.1772
- 委 比 0.00%
- 總股本 4.99万
- 歷史最高 1236.24
- 量 比 0.11
- 振 幅 16.53%
- 歷史最低 0.1772
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
AEON Biopharma shares are trading higher after the company announced that the FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence.
AEON Biopharma shares are trading higher after the company announced that the FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence.
10-01 02:13
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Biopharma announced progress in developing ABP-450, a biosimilar to BOTOX®, following a Type 2b meeting with the FDA. The FDA supports a streamlined development path, allowing AEON to potentially avoid a standalone comparative efficacy study. The company plans to submit an IND for a CMAP pharmacodynamic study in Q4 2026 and leverage existing comparative human evidence and analytical data to support biosimilarity. AEON aims to reduce clinical...
09-30 12:00
AEON Biopharma shares are trading higher after the company reported pilot study results showing its ABP‑450 had comparable potency loss and oxidation patterns to Botox under thermal and oxidative stress.
AEON Biopharma shares are trading higher after the company reported pilot study results showing its ABP‑450 had comparable potency loss and oxidation patterns to Botox under thermal and oxidative stress.
09-10 19:43
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
AEON Biopharma announced positive results from a pilot study comparing ABP-450 to BOTOX® under thermal and oxidative stress. Both products showed comparable potency loss under thermal stress and similar oxidation patterns at methionine sites under oxidative stress. These findings provide analytical evidence supporting structural comparability and will inform AEON's planned multi-lot comparability study. The study highlights the importance of forc...
09-09 12:00
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
AEON Biopharma, a biopharmaceutical company developing ABP-450 as a biosimilar to BOTOX for therapeutic use, announced that its management will host in-person investor meetings at the Lake Street Capital Markets' BIG10 Conference in New York City on September 10, 2026. ABP-450, manufactured by Daewoong Pharmaceutical, aims for full-label U.S. market entry in the $3 billion therapeutic neurotoxin market.
08-31 12:00
AEON Biopharma Designates Paul Lee As Chief Regulatory Office
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief...
08-24 20:05
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
AEON Biopharma appoints Dr. Paul Lee as acting Chief Regulatory Officer to lead the regulatory strategy for ABP-450, a biosimilar to BOTOX. Dr. Lee, with extensive FDA experience, will oversee interactions with the FDA and guide the development program under the 351(k) biosimilar pathway. AEON aims to achieve full-label U.S. market entry for ABP-450, targeting the $3 billion therapeutic neurotoxin market.
08-24 12:00
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON Biopharma announced progress in ABP-450's development as a BOTOX biosimilar, achieving 98% sequence coverage with 100% amino acid identity and confirming the critical C430-C454 disulfide bond. FDA feedback from an upcoming Type 2b meeting will guide future clinical studies, supporting the molecule's potential for full U.S. market entry.
08-19 12:00
AEON Biopharma Regains NYSE American Compliance
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC ("NYSE Amer...
08-04 04:22
